Press release
Pulmonary Arterial Hypertension Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies
Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Pulmonary Arterial Hypertension Treatment Landscape. Click here to read more @ Pulmonary Arterial Hypertension Pipeline Outlook [https://www.delveinsight.com/sample-request/pulmonary-arterial-hypertension-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Pulmonary Arterial Hypertension Pipeline Report
* In March 2025:- United Therapeutics conducted a study is to assess the effect of early and rapid treprostinil therapy for mean pulmonary artery pressure (mPAP) reduction to improve right ventricular (RV) function and reverse RV remodeling in participants with pulmonary arterial hypertension (PAH).
* In March 2025:- Actelion announced a study is to demonstrate superiority of macitentan 75 milligrams (mg) in prolonging the time to the first clinical events committee (CEC)-adjudicated morbidity or mortality (M/M) event in participants with symptomatic pulmonary arterial hypertension (PAH) compared to macitentan 10 mg.
* In March 2025: Merck Sharp & Dohme LLC announced a study are to evaluate the safety and tolerability, and pharmacokinetics (PK) of sotatercept over 24 weeks of treatment in children greater than or equal to 1 to
* DelveInsight's Pulmonary Arterial Hypertension Pipeline analysis depicts a robust space with 55+ active players working to develop 55+ pipeline treatment therapies.
* The leading Pulmonary Arterial Hypertension Companies such as Merck Sharp & Dohme, Acceleron Pharma, Liquidia Technologies, Gossamer Bio, Resverlogix, PhaseBio Pharmaceuticals, Pharmosa BioPharm, Complexa, Gmax Biopharm Australia, Mezzion, Radikal Therapeutics, Galectin Therapeutics, Altavant Sciences, Ribomic and others.
* Promising Pulmonary Arterial Hypertension Therapies such as TPN171H, Tadalafil, Treprostinil Palmitil, Satralizumab (Genetical Recombination), PF-07868489, Sotatercept and others.
Discover groundbreaking developments in Pulmonary Arterial Hypertension therapies! Gain in-depth knowledge of key Pulmonary Arterial Hypertension clinical trials, emerging drugs, and market opportunities @ Pulmonary Arterial Hypertension Clinical Trials Assessment [https://www.delveinsight.com/sample-request/pulmonary-arterial-hypertension-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Pulmonary Arterial Hypertension Emerging Drugs Profile
* Sotatercept: Acceleron Pharma
Sotatercept is a first-in-class therapeutic fusion protein comprised of the extracellular domain of human activin receptor type IIA, fused to the Fc domain of human immunoglobulin G1 (IgG1). It provides balance of the growth-promoting activin growth differentiation factor pathway, and the growth-inhibiting BMP pathway by serving as a ligand trap for the TGF- superfamily. The United States Food and Drug Administration (FDA) has granted Orphan Drug designation and Breakthrough Therapy designation to sotatercept for the treatment of PAH; the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to sotatercept for the treatment of PAH. Sotatercept is in Phase III clinical trial for the treatment of PAH.
* LIQ861: Liquidia Technologies
LIQ861 is an investigational, inhaled dry powder formulation of treprostinil designed using the Company's novel PRINT technology and engineered with the goal of enhancing deep-lung delivery of treprostinil in PAH patients by means of a convenient, palm-sized dry powder inhaler. Liquidia resubmits New Drug Application for LIQ861 under the 505(b)(2) regulatory pathway for the treatment of pulmonary arterial hypertension (PAH).
The Pulmonary Arterial Hypertension Pipeline report provides insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Pulmonary Arterial Hypertension with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Pulmonary Arterial Hypertension Treatment.
* Pulmonary Arterial Hypertension Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Pulmonary Arterial Hypertension Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Pulmonary Arterial Hypertension market
Stay informed about the Pulmonary Arterial Hypertension pipeline trends! Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Pulmonary Arterial Hypertension Unmet Needs [https://www.delveinsight.com/sample-request/pulmonary-arterial-hypertension-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Pulmonary Arterial Hypertension Companies
Merck Sharp & Dohme, Acceleron Pharma, Liquidia Technologies, Gossamer Bio, Resverlogix, PhaseBio Pharmaceuticals, Pharmosa BioPharm, Complexa, Gmax Biopharm Australia, Mezzion, Radikal Therapeutics, Galectin Therapeutics, Altavant Sciences, Ribomic and others.
Pulmonary Arterial Hypertension pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Oral
* Parenteral
* Intravitreal
* Subretinal
* Topical
* Molecule Type
Pulmonary Arterial Hypertension Products have been categorized under various Molecule types such as
* Monoclonal Antibody
* Peptides
* Polymer
* Small molecule
* Gene therapy
* Product Type
Transform your understanding of the Pulmonary Arterial Hypertension Pipeline! See the latest progress in drug development and clinical research @ Pulmonary Arterial Hypertension Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/pulmonary-arterial-hypertension-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Pulmonary Arterial Hypertension Pipeline Report
* Coverage- Global
* Pulmonary Arterial Hypertension Companies- Merck Sharp & Dohme, Acceleron Pharma, Liquidia Technologies, Gossamer Bio, Resverlogix, PhaseBio Pharmaceuticals, Pharmosa BioPharm, Complexa, Gmax Biopharm Australia, Mezzion, Radikal Therapeutics, Galectin Therapeutics, Altavant Sciences, Ribomic and others.
* Pulmonary Arterial Hypertension Therapies- TPN171H, Tadalafil, Treprostinil Palmitil, Satralizumab (Genetical Recombination), PF-07868489, Sotatercept and others.
* Pulmonary Arterial Hypertension Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Pulmonary Arterial Hypertension Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Stay Ahead in Oncology Research-Access the Full Pulmonary Arterial Hypertension Pipeline Analysis Today! @ Pulmonary Arterial Hypertension Drugs and Companies [https://www.delveinsight.com/sample-request/pulmonary-arterial-hypertension-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Pulmonary Arterial Hypertension: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Pulmonary Arterial Hypertension - DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Sotatercept: Acceleron Pharma
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* GB-002: Gossamer Bio
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* Apabetalone: Resverlogix
* Drug profiles in the detailed report.....
* Preclinical/Discovery Stage Products
* R107: Radikal Therapeutics
* Drug profiles in the detailed report.....
* Inactive Products
* Pulmonary Arterial Hypertension Key Companies
* Pulmonary Arterial Hypertension Key Products
* Pulmonary Arterial Hypertension- Unmet Needs
* Pulmonary Arterial Hypertension- Market Drivers and Barriers
* Pulmonary Arterial Hypertension- Future Perspectives and Conclusion
* Pulmonary Arterial Hypertension Analyst Views
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=pulmonary-arterial-hypertension-clinical-trials-and-studies-ema-pdma-fda-approvals-mechanism-of-action-roa-nda-ind-and-companies]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/pulmonary-arterial-hypertension-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Pulmonary Arterial Hypertension Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies here
News-ID: 3913431 • Views: …
More Releases from ABNewswire
AI Video Analytics Market to Reach $17.24 Bn by 2031, Driven by Smart City Adopt …
Mordor Intelligence has published a new report on the AI Video Analytics Market, offering a comprehensive analysis of trends, growth drivers, and future projections.
AI Video Analytics Market Overview
The AI Video Analytics Market [https://www.mordorintelligence.com/industry-reports/global-ai-video-analytics-market?utm_source=abnewswire] is witnessing steady expansion as organizations adopt data-driven video intelligence to support security, operational monitoring, and customer insight initiatives. According to Mordor Intelligence, the AI Video Analytics Market size was valued at USD 5.04 billion in 2025…
Las Vegas Hard Rock Band Foundry Launches Bold Coffee Line That Matches Their So …
Foundry, a Las Vegas-based hard rock band, has expanded from the stage to the kitchen counter with the launch of their Hard Rock Roast coffee. The coarse-ground coffee features notes of dark chocolate, brown sugar, and rich molasses, designed to fuel late nights and loud mornings for fans and coffee enthusiasts alike.
Most coffee brands start with market research, focus groups, and corporate boardrooms. Foundry started with amplifiers, drum kits, and…
Counselling Birmingham UK: Phinity Therapy Responds to Rising Demand for Marriag …
Phinity Therapy, a trusted provider of psychotherapy and counselling services in Birmingham, UK, is responding to rising demand for marriage and relationship counselling. As searches for counselling near me increase across the city, the practice continues to support individuals and couples seeking professional, accessible counselling services in Birmingham.
Birmingham, UK - As awareness around mental health and emotional wellbeing continues to grow, Birmingham is experiencing a notable rise in demand for…
Architect-Led Design Draws Focus as Sunshine Coast Projects Face Cost Pressures
As construction costs rise and development continues across the Sunshine Coast, architect-led design is drawing increased attention. Industry commentary suggests early design involvement may help manage affordability, reduce planning risk, and limit costly project changes.
SUNSHINE COAST, QLD - January 12, 2026 - Rising construction costs and continued development activity across the Sunshine Coast are changing how residential and commercial projects are being planned. Architects working in the region say early…
More Releases for Pulmonary
Innovation In Pulmonary Drug Delivery Devices Industry Trends Gaining Momentum i …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Pulmonary Drug Delivery Devices Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The market size for pulmonary drug delivery devices has experienced significant growth in the past few years. The market is projected to increase from $49.52 billion in 2024 to $52.8 billion in 2025,…
Chronic Pulmonary Aspergillosis Drugs Market - Revitalizing Lungs: Revolutionary …
Newark, New Castle, USA - new report, titled Chronic Pulmonary Aspergillosis Drugs Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Chronic Pulmonary Aspergillosis Drugs market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Chronic Pulmonary Aspergillosis Drugs market. The report offers…
Global Pulmonary Arterial Hypertension Market Size
According to a new market research report published by Global Market Estimates, the Global Pulmonary Arterial Hypertension Market is projected to grow at a CAGR of 5.2% from 2022 to 2027.
Congenital heart diseases and other ailments such as HIV infection, chronic liver disease (cirrhosis), and connective tissue disorders (scleroderma, lupus, and others) are fueling market expansion.
Browse 153 Market Data Tables and 113 Figures spread through 185 Pages and in-depth TOC…
New Study: Pulmonary Drugs Market Report
The pulmonary drugs market is expected to witness unprecedented growth in the near future, thanks to large number of approvals from the FDA. The FDA approved a large number of pulmonary drugs for major illnesses like small-cell lung cancer, tuberculosis, and pneumonia over the past few years. Additionally, newly approved drugs also treat newly found diseases like obstructive sleep apnea. These approvals are in line with the recent trend of…
Pulmonary Drugs Market Forecast till 2025
Pulmonary Drugs Market – Boon for Diseased Lungs
Pulmonary drugs can treat wide range of conditions, which are included within the ambit of pulmonary diseases such as pneumonia, allergic rhinitis, pulmonary hypertension, and others. . Pulmonary drugs provide medications for all types of pulmonary diseases, which is expected to fuel market growth in near future. The World Health Organization (WHO) states that most respiratory diseases are preventable and can be treated…
Pulmonary Drug Delivery Devices Market: Demand for Pulmonary Drug Delivery Devic …
This report on pulmonary drug delivery devices studies the current as well as future prospects of the market globally. The stakeholders of this report include companies and intermediaries engaged in the manufacture and commercialization of various pulmonary/respiratory drugs and/or drug-device combinations as well as new entrants planning to enter this market.
This report comprises an elaborate executive summary along with a market snapshot providing overall information of various segments and sub-segments…
